Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy

Exclusion Criteria

• •Patients with a history of a rheumatic autoimmune disease other than RA or with significant systemic involvement secondary to RA;
• •Previous exposure to biologic anti-rheumatic therapies, including investigational compounds;
• •Exposure to TNF-alpha antagonist treatment \< 12 weeks prior to visit 2;
• •Chronic or ongoing active infectious disease requiring systemic treatment;
• •Clinically significant cardiac disease; History of significant cerebrovascular disease;
• •Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral psychiatric disease, or evidence of demyelinating disease;
• •Known HIV positive; Serologic evidence of Hepatitis B infection; Positive test for Hepatitis C; Positive plasma / white cell JC Virus PCR;
• •Serum IgG \< lower limit of normal;
• •Breast feeding women or women with a positive pregnancy test at screening;
• •Current participation in any other interventional clinical study;
• •Patients known or suspected of not being able to comply with a study protocol.